EMP2 and neoplasm: EMP2 levels are significantly increased during the progression from non-malignant glandular to ductal carcinoma in situ, invasive ductal carcinoma, and lymph node metastasis [90], suggesting the potential role of EMP2 in the late stage of breast cancer in association with tumor invasion and metastasis [91].